TearSolutions: Naturally Treating Dry Eye (225)
Innovation4Alpha
English - July 04, 2022 21:00 - 23 minutes - 16 MB - ★★★★ - 4 ratingsInvesting Business innovation investing healthcare Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Sage Medical: Bringing Intelligence to Medical Coding & Billing (224)
Next Episode: MRG Health: Chronic Care Management on a New Level (226)
TearSolutions' lead product, called Lacripep, delivers what no other approved or pipeline drug has been able to: rapid healing of the ocular surface and relief of dry eye symptoms with a best-in-class safety and comfort profile. This was all proven in their first-in-human clinical trial which has led to formal written FDA alignment on our clinical and regulatory path to an unrestricted general Dry Eye indication (which is the same path a dry eye drug called Xiidra took, which sold to Novartis for $5.3B).
The company is raising capital to get Lacripep back into the clinic for the first of two Phase III trials.